Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has provided an announcement.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in a phase 2 clinical trial for HLX43, an antibody-drug conjugate targeting PD-L1, to treat recurrent/metastatic esophageal squamous cell carcinoma (ESCC) in mainland China. The study aims to evaluate the efficacy and safety of HLX43, with plans to expand clinical trials to other cancer types. The announcement highlights the company’s continued efforts in innovative cancer therapies, although no PD-L1 targeting ADCs have yet been approved globally.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry and focuses on developing and commercializing monoclonal antibody drugs and antibody-drug conjugates. The company specializes in treating various forms of cancer, with a strong market focus on advanced and metastatic solid tumors.
YTD Price Performance: -15.40%
Average Trading Volume: 761,561
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$10.9B
For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.